Neuren Pharmaceuticals Limited ( (AU:NEU) ) has issued an announcement.
Neuren Pharmaceuticals Limited has announced an update regarding its ongoing on-market buy-back program. As of March 18, 2025, the company reported buying back a total of 1,625,156 ordinary fully paid securities, including 21,905 securities purchased on the previous day. This buy-back initiative is part of Neuren’s strategy to manage its capital structure and potentially enhance shareholder value.
More about Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on the development of therapies for neurodevelopmental disorders. The company is primarily engaged in creating innovative treatments to address unmet medical needs in this specialized market segment.
YTD Price Performance: -2.18%
Average Trading Volume: 670
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $956.1M
Find detailed analytics on NEU stock on TipRanks’ Stock Analysis page.